SCHEMBL17812908

SCHEMBL17812908

Cc1cccc(-c2nc(Nc3cc(C#N)ccn3)cc(NC(C)C)n2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 4/20 0.48
ABCB1 P08183 1/20 0.48
ABCC1 P33527 1/20 0.48
TGFBR1 P36897 3/20 0.45
MAP3K12 Q12852 3/20 0.41
CYP1A2 P05177 2/20 0.40
GRM5 P41594 2/20 0.39
TRPV4 Q9HBA0 1/20 0.39
CLK4 Q9HAZ1 3/20 0.37
MAP4K4 O95819 1/20 0.37
ABL1 P00519 1/20 0.37
LCK P06239 1/20 0.37
FYN P06241 1/20 0.37
IGF1R P08069 1/20 0.37
LTK P29376 1/20 0.37
KDR P35968 1/20 0.37
MAP2K2 P36507 1/20 0.37
MAPK8 P45983 1/20 0.37
MAPK9 P45984 1/20 0.37
CLK2 P49760 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16392139 0.85 IDH1 (0.53) ABCG2ABCB1ABCC1CYP1A2IDH1
SCHEMBL16391808 0.84 TGFBR1 (0.46) ABCG2ABCB1ABCC1TGFBR1CYP1A2
SCHEMBL17812903 0.83 TGFBR1 (0.46) TGFBR1MAP3K12CYP1A2CLK4MAP4K4
SCHEMBL17812899 0.83 CYP1A2 (0.52) ABCG2ABCB1ABCC1TGFBR1CYP1A2
SCHEMBL17812909 0.81 IDH2 (0.50) TGFBR1MAP3K12CYP1A2CLK4MAP4K4
SCHEMBL17812917 0.80 TGFBR1 (0.57) ABCG2ABCB1ABCC1TGFBR1CYP1A2
SCHEMBL17812902 0.77 TGFBR1 (0.59) ABCG2ABCB1ABCC1TGFBR1CYP1A2
SCHEMBL16392068 0.76 ABCG2 (0.58) ABCG2ABCB1ABCC1CYP1A2GRM5
SCHEMBL17812901 0.76 TGFBR1 (0.46) ABCG2ABCB1ABCC1TGFBR1CYP1A2
SCHEMBL17812910 0.75 CYP1A2 (0.55) TGFBR1CYP1A2IDH1IDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160158230-A1 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER SERVIER PHARMACEUTICALS LLC 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160158230-A1 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER IDH2, IDH3B, IDH3A ABCG2 889/4885ABCB1 828/4885ABCC1 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.